Psoriatic Arthritis

Major Improvements in Psoriatic Arthritis Disease Activity Achieved With Methotrexate

Major Improvements in Psoriatic Arthritis Disease Activity Achieved With Methotrexate

By

Methotrexate with targeted escalation resulted in significant improvement in the skin, joint, dactylitis, enthesitis, and functional domains of PsA.

Abatacept Improved Patient-Reported Outcomes in Psoriatic Arthritis

Abatacept Improved Patient-Reported Outcomes in Psoriatic Arthritis

By

Abatacept treatment improved patient-reported outcomes in patients with psoriatic arthritis compared with placebo.

Very Low Disease Activity Validated as Remission Target for Psoriatic Arthritis

Very Low Disease Activity Validated as Remission Target for Psoriatic Arthritis

By

Data suggest that very low disease activity may be an appropriate target for remission in patients with psoriatic arthritis treated with golimumab.

Secukinumab Provides Sustained Remission for Psoriatic Arthritis in Post Hoc Analysis

Secukinumab Provides Sustained Remission for Psoriatic Arthritis in Post Hoc Analysis

By

A post hoc analysis of the FUTURE 2 study showed that secukinumab provides sustained PASDAS-defined remission in psoriatic arthritis.

Ixekizumab Compared With Adalimumab in Head-to-Head PsA Study

Ixekizumab Compared With Adalimumab in Head-to-Head PsA Study

By

The SPIRIT H2H trial (N=566) randomized PsA patients to receive ixekizumab (160mg starting dose followed by 80mg every 4 weeks) or adalimumab (40mg every 2 weeks) for 52 weeks.

Ustekinumab May Benefit Subclinical Enthesopathy in Patients With Psoriasis

Ustekinumab May Benefit Subclinical Enthesopathy in Patients With Psoriasis

By

Researchers investigated whether sonographically determined subclinical enthesopathy in patients with moderate to severe psoriasis regressed under therapy with ustekinumab.

Metabolic Syndrome, Psoriatic Arthritis Highly Prevalent in Patients With Plaque Psoriasis

Metabolic Syndrome, Psoriatic Arthritis Highly Prevalent in Patients With Plaque Psoriasis

By

Metabolic syndrome and psoriatic arthritis were highly prevalent comorbidities in patients with plaque psoriasis.

Managing Psoriatic Arthritis: Updated 2018 Recommendations From ACR/NPF

Managing Psoriatic Arthritis: Updated 2018 Recommendations From ACR/NPF

By

The American College of Rheumatology and the National Psoriasis Foundation have released 2018 joint recommendations for the treatment of psoriatic arthritis.

New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Therapy Option

New Psoriatic Arthritis Guidelines Recommend TNFi as First-Line Therapy Option

By

The guideline is jointly authored by the American College of Rheumatology (ACR) and the National Psoriasis Foundation (NPF).

Using Acute-Phase Reactants to Evaluate Inflammation in Patients With Psoriatic Arthritis

Using Acute-Phase Reactants to Evaluate Inflammation in Patients With Psoriatic Arthritis

By

Data regarding assessment of systemic inflammation using acute-phase reactants are limited.

Higher Cardiovascular Risk Seen With Psoriatic Arthritis

Higher Cardiovascular Risk Seen With Psoriatic Arthritis

Cardiovascular risk should be carefully evaluated in patients with psoriatic arthritis.

Comparing Physician and Patient Reports of Psoriatic Arthritis Remission

Comparing Physician and Patient Reports of Psoriatic Arthritis Remission

By

Researchers compared definitions of remission and low disease activity in patients with psoriatic arthritis.

Comparing Remission, Low Disease Definitions in Psoriatic Arthritis

Comparing Remission, Low Disease Definitions in Psoriatic Arthritis

By

Investigators examined the performance of various definitions in patients with PsA and psoriasis.

Assessing the Accuracy of Questionnaire-Based Screening Tools for Detection of Psoriatic Arthritis

Assessing the Accuracy of Questionnaire-Based Screening Tools for Detection of Psoriatic Arthritis

By

Researchers reviewed the accuracy and characteristics of questionnaire-based PsA screening tools.

Filgotinib Effective for Treatment of Active Psoriatic Arthritis

Filgotinib Effective for Treatment of Active Psoriatic Arthritis

By

Data show that filgotinib is effective for the treatment of active psoriatic arthritis.

Gout Associated With Psoriatic Arthritis, Psoriasis in Adults

Gout Associated With Psoriatic Arthritis, Psoriasis in Adults

By

Data show an increased prevalence of psoriasis in patients with gout compared with patients without gout.

Influenza Vaccination Low in Rheumatoid Arthritis, Psoriatic Arthritis

Influenza Vaccination Low in Rheumatoid Arthritis, Psoriatic Arthritis

By

Patients with rheumatoid arthritis or psoriatic arthritis have a low influenza vaccination rate, despite the recommendation from the CDC to be vaccinated annually.

Sustained Joint and Skin Improvement Found With Bimekizumab in Psoriatic Arthritis

Sustained Joint and Skin Improvement Found With Bimekizumab in Psoriatic Arthritis

Christopher T. Ritchlin, MD, MPH, discusses updated bimekizumab data from the BE-ACTIVE trial.

Statins May Decrease C-Reactive Protein Levels in Psoriatic Arthritis

Statins May Decrease C-Reactive Protein Levels in Psoriatic Arthritis

By

Statin therapy was associated lower CRP levels in psoriatic arthritis treated with statins, possibly indicating decreased systemic inflammation.

No Significant Risk for Atrial Fibrillation, CV Events in PsA Receiving Ustekinumab vs TNF Inhibitors

No Significant Risk for Atrial Fibrillation, CV Events in PsA Receiving Ustekinumab vs TNF Inhibitors

By

The primary and secondary outcomes included incident AF or a composite CV event that included myocardial infarction, stroke, and coronary revascularization.

Ustekinumab and Secukinumab Safe, Efficacious for Psoriatic Arthritis

Ustekinumab and Secukinumab Safe, Efficacious for Psoriatic Arthritis

By

Among a new line of biological and targeted synthetic DMARD, ustekinumab and secukinumab have shown favorable safety and efficacy profiles for psoriasis and arthritis, respectively in patients with psoriatic arthritis.

Greater Entheseal Damage, Inflammation Observed in Psoriatic Arthritis vs Ankylosing Spondylitis

Greater Entheseal Damage, Inflammation Observed in Psoriatic Arthritis vs Ankylosing Spondylitis

By

Patients with psoriatic arthritis had greater entheseal insertion damage scores compared with patients with ankylosing spondylitis.

Radiographic Changes in PsA: Conventional Synthetic DMARDs vs Anti-TNF Therapy

Radiographic Changes in PsA: Conventional Synthetic DMARDs vs Anti-TNF Therapy

By

Investigators assessed radiographic progression in patients with psoriatic arthritis following transition from conventional synthetic disease-modifying rheumatic drugs to anti-tumor necrosis factor-α therapy.

Use of DAPSA28 for Assessment of Disease Activity in Psoriatic Arthritis

Use of DAPSA28 for Assessment of Disease Activity in Psoriatic Arthritis

By

Investigators sought to determine the validity of using a simplified scoring tool that assesses 28 joint counts compared with the original 66/68 joint counts in patients with psoriatic arthritis.

PsA Activity During and After Pregnancy Affected by Biologic Therapy

PsA Activity During and After Pregnancy Affected by Biologic Therapy

By

Investigators explore the impact of pregnancy on PsA disease activity, as well as the effect of biologic therapy on PsA disease activity during and following pregnancy.

Risk for Type 2 Diabetes, Cardiovascular Disease Elevated in Patients With Psoriatic Arthritis

Risk for Type 2 Diabetes, Cardiovascular Disease Elevated in Patients With Psoriatic Arthritis

By

Risk for type 2 diabetes, ischemic heart disease, and peripheral vascular disease was elevated among patients with psoriatic arthritis compared with the general population.

Sustained Improvements in PsA With Certolizumab Pegol Monotherapy, DMARD Combination

Sustained Improvements in PsA With Certolizumab Pegol Monotherapy, DMARD Combination

By

Results from the RAPID-PsA study showed that patients with PsA who are treated with certolizumab pegol sustained improvements over the course of 4 years when it is taken as a monotherapy or concomitant with DMARDs.

Incidence, Predictors of Orthopedic Surgery in Psoriatic Arthritis

Incidence, Predictors of Orthopedic Surgery in Psoriatic Arthritis

By

Researchers quantified the incidence of orthopedic procedures in patients with psoriatic arthritis.

Effects of Age, Disease Duration on Bone Erosions in Psoriasis, Psoriatic Arthritis

Effects of Age, Disease Duration on Bone Erosions in Psoriasis, Psoriatic Arthritis

By

Data show that psoriatic arthritis acts as a strong enhancer of age-related catabolic bone damage.

Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis

Rheumatologist-Assessed vs Criteria for Inflammatory Back Pain in Psoriatic Arthritis

By

Rheumatologist-assessed inflammatory back pain (IBP) or the criteria for IBP developed for ankylosing spondylitis might not perform well when determining axial involvement in psoriatic arthritis.

Sign Up for Free e-newsletters